Response to treatment
| CNS response in LMM | CNS response assessment methods | LM-RANO Response* | |||||
| CNS Radiologic Response (RECIST 1.1) | CNS Radiologic Response (irRC) | CNSCytologic Response | CNSClinical Response | Extracranial Radiologic Response (RECIST 1.1) | |||
| No. evaluable patients | 13† | 11 | 11 | 7 | 13 | 4 | 13 |
| Complete Response | 2 (15) | 0 (0) | 1 (8) | N/A | 2 (15) | 0 (0) | Response2 (15) |
| Partial Response | 1 (8) | 1 (8) | 1 (8) | N/A | 0 (0) | 0 (0) | |
| Stable Disease | 2 (15) | 7 (54) | 5 (38) | N/A | 3 (23) | 1 (8) | 3 (23) |
| Progressive Disease | 8 (62) | 3 (23) | 4 (31) | N/A | 8 (62) | 3 (23) | 8 (62) |
| Not evaluable | 0 (0) | 2 (15) | 2 (15) | 6 | 0 (0) | 9 (69) | 0 (0) |
| Present | 4 (31) | ||||||
| Absent | 3 (23) | ||||||
*LM-RANO: Leptomeningeal Metastasis Response Assessment in Neuro-Oncology.
†Primary Response assessment for Overall CNS response as radiologic in 10 cases, and clinical in 3 cases.
CNS, central nervous system; irRC, immune-related response criteria; LMM, leptomeningeal metastasis; N/A, not applicable; RECIST, response evaluation criteria for solid tumors.